Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Li, Chuanwei ^a,b   Zhang, Wen ^c   Zhou, Faying ^a,b   Chen, Caiyu ^a,b   Zhou, Liang ^c   Li, Yafei ^c   Liu, Ling ^c   Pei, Fang ^a,b   Luo, Hao ^a,b   Hu, Zhangxue ^a,b   Cai, Jing ^a,b   Zeng, Chunyu ^a,b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Institute of Cardiology   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HYPERTENSION; META ANALYSIS; MUSCULOSKELETAL INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXAZOLIDINONES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84886603461     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077049     Document Type: Article

References (42)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-57.
2. Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, et al. (2012) Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol 158: 93-100.
3. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart Disease and Stroke Statistics-2011 update: A Report From the American Heart Association. Circulation 123: e18-e129.
4. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-81.
5. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, et al. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15.
6. Jafri H, Alsheikh-Ali AA, Karas RH, (2010) Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 153: 800-8.
7. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES, (2005) Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45: 185-97.
8. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, et al. (1999) Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19: 1105-10.
9. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BH, et al. (2005) Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 54: 3554-9.
10. Foger B, Luef G, Ritsch A, Schmidauer C, Doblinger A, et al. (1995) Relationship of high-density lipoprotein subfractions and cholesteryl ester trasfer protein in plasma to carotid artery wall thickness. J Mol Med 73: 369-72.
11. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, et al. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323: 1234-38.
12. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, et al. (2008) Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299: 2777-88.
13. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, et al. (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406: 203-7.
14. Hermann F, Enseleit F, Spieker LE, Périat D, Sudano I, et al. (2009) Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res 123: 460-5.
15. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, et al. (2012) Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 163: 515-21.
16. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, et al. (2002) Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105: 2159-65.
17. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, et al. (2005) Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95: 1085-8.
18. Bisoendial RJ, Hovingh GK, El Harchaoui K, Levels JH, Tsimikas S, et al. (2005) Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 25: e133-4.
19. Davidson MH, McKenney JM, Shear CL, Revkin JH, (2006) Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 48: 1774-81.
20. McKenney JM, Davidson MH, Shear CL, Revkin JH, (2006) Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48: 1782-90.
21. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, et al. (2008) Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118: 2515-22.
22. Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, et al. (2008) Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 28: 148-54.
23. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, et al. (2009) Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157: 352-360.
24. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, et al. (2007) Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370: 1907-14.
25. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, et al. (2011) Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306: 2099-109.
26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
27. Hozo SP, Djulbegovic B, Hozo I, (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5: 13.
28. Liu T, Li G, Li L, Korantzopoulos P, (2007) Association between C-reactive protein and recurrence of atrial fibrillation after successfulelectrical cardioversion: a meta-analysis. J Am Coll Cardiol 49: 1642-8.
29. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, et al. (2010) Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2010.Cochrane Database Syst Rev 7: CD006401.
30. Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, (2007) LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 40: 310-6.
31. Sahoo D, Trischuk TC, Chan T, Drover VA, Ho S, et al. (2004) ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J Lipid Res 45: 1122-31.
32. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556-63.
33. Vergeer M, Stroes ES, (2009) The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 104: 32E-8E.
34. Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, et al. (2011) Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 52: 2169-76.
35. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, et al. (2009) Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150: 2211-9.
36. Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, et al. (2012) Torcetrapib impairs endothelial function in hypertension. Eur Heart J 33: 1615-24.
37. Connelly MA, Parry TJ, Giardino EC, Huang Z, Cheung WM, et al. (2010) Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol 55: 459-68.
38. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, et al. (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304-16.
39. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, et al. (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338: b92.
40. Ray K, Wainwright NW, Visser L, Witteman J, Breteler M, et al. (2012) Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 98: 780-5.
41. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, et al. (2010) Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 121: 366-74.
42. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, et al. (2012) Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 367: 2089-99.